Eagle Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Eagle Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$14.4M	Sell	1,356,779 -580,930	-30%	-$5.5M	0.07%	230
2024 Q2	$15.6M	Buy	1,937,709 +1,386,691	+252%	+$14.9M	0.08%	213
2024 Q1	$7.82M	Buy	551,018 +100,562	+22%	+$1.17M	0.04%	329
2023 Q4	$3.66M	Buy	+450,456	New	+$2.36M	0.02%	409
2020 Q4	–	Sell	-63,874	Closed	-$2.06M	–	623
2020 Q3	$2.06M	Sell	63,874 -644,786	-91%	-$19.8M	0.01%	442
2020 Q2	$19.3M	Buy	708,660 +275,325	+64%	+$9.05M	0.11%	218
2020 Q1	$13M	Buy	433,335 +107,353	+33%	+$2.85M	0.08%	243
2019 Q4	$9.02M	Buy	+325,982	New	+$7.41M	0.04%	327

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Eagle Asset Management's IOVA Position: Q3 2024 in Review

Eagle Asset Management reduced its Iovance Biotherapeutics (IOVA) stake by 30% in Q3 2024, selling an estimated $5.5M and leaving 1,356,779 shares worth $14.4M. The position accounts for 0.07% of the portfolio, ranked #230.

Eagle Asset Management first reported a position in IOVA in Q4 2019 and has held it in 8 quarters since. The position peaked at $19.3M in Q2 2020. 286 funds tracked by Wall St. Rank hold IOVA as of Q3 2024.

Eagle Asset Management held 1,356,779 shares of Iovance Biotherapeutics worth $14.4M as of Q3 2024.
Eagle Asset Management sold 580,930 Iovance Biotherapeutics shares in Q3 2024, an estimated $5.5M.
Iovance Biotherapeutics made up 0.07% of Eagle Asset Management's portfolio in Q3 2024, its #230 holding.
Eagle Asset Management first reported a position in Iovance Biotherapeutics in Q4 2019 and has held it in 8 quarters since.
Eagle Asset Management's Iovance Biotherapeutics position peaked at $19.3M in Q2 2020.
286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2024.

Based on Eagle Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.